 |
 |
 |
 |
|
|
|
|
 |
|
|
 |
|
|
|
|
| |
|||||||||||||||||
|
|
|
|
|
|
|
|||||||||||
|
|||||||||||||||||
|
EID
Home | Ahead of Print | Past
Issues | EID Search | Contact
Us | Announcements | Suggested
Citation | Submit Manuscript
Volume 11, Number 7, July 2005 SARS Vaccine DevelopmentShibo Jiang,* Yuxian He,* and Shuwen Liu* |
|
|
|
 |
|
| Back to article | |
|
Figure 1. Strategy for designing vaccines for severe acute respiratory syndrome (SARS) using inactivated SARS-associated coronavirus. This virus expresses several structural proteins, including nucleocapsid (N), membrane (M), envelope (E), and spike (S). |
|
|
|
|
|
EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z |
|
|
This page last reviewed June 13, 2005 |
|
|
Emerging
Infectious Diseases Journal |
|